No abstract

Over 100 genetic loci harbor schizophrenia associated variants, yet how these variants confer liability is uncertain. The CommonMind Consortium sequenced RNA from dorsolateral prefrontal cortex of schizophrenia cases (N = 258) and control subjects (N = 279), creating a resource of gene expression and its genetic regulation. Using this resource, ~20% of schizophrenia loci have variants that could contribute to altered gene expression and liability. In five loci, only a single gene was involved: FURIN, TSNARE1, CNTN4, CLCN3, or SNAP91. Altering expression of FURIN, TSNARE1, or CNTN4 changes neurodevelopment in zebrafish; knockdown of FURIN in human neural progenitor cells yields abnormal migration. Of 693 genes showing significant case/control differential expression, their fold changes are ≤ 1.33, and an independent cohort yields similar results. Gene co-expression implicates a network relevant for schizophrenia. Our findings show schizophrenia is polygenic and highlight the utility of this resource for mechanistic interpretations of genetic liability for brain diseases.

Defective brain insulin signaling has been suggested to contribute to the cognitive deficits in patients with

73Over 100 genetic loci harbor schizophrenia associated variants, yet how these common 74 variants confer risk is uncertain. The CommonMind Consortium has sequenced dorsolateral 75 prefrontal cortex RNA from schizophrenia cases (n=258) and control subjects (n=279), creating 76 the largest publicly available resource to date of gene expression and its genetic regulation; ~5 77 times larger than the latest release of GTEx. Using this resource, we find that ~20% of the 78 schizophrenia risk loci have common variants that could explain regulation of brain gene 79 expression. In five loci, these variants modulate expression of a single gene: FURIN, TSNARE1, 80 CNTN4, CLCN3 or SNAP91. Experimentally altered expression of three of them, FURIN, 81 TSNARE1, and CNTN4, perturbs the proliferation and apoptotic index of neural progenitors and 82 leads to neuroanatomical deficits in zebrafish. Furthermore, shRNA mediated knock-down of 83 FURIN in neural progenitor cells derived from human induced pluripotent stem cells produces 84 abnormal neural migration. Although 4.2% of genes (N = 693) display significant differential 85 expression between cases and controls, 44% show some evidence for differential expression. 86All fold changes are ≤ 1.33, and an independent cohort yields similar differential expression for 87 these 693 genes (r = 0.58). These findings are consistent with schizophrenia being highly 88 polygenic, as has been reported in investigations of common and rare genetic variation. Co-89 expression analyses identify a gene module that shows enrichment for genetic associations and 90 is thus relevant for schizophrenia. Taken together, these results pave the way for mechanistic 91 interpretations of genetic liability for schizophrenia and other brain diseases. 4The human brain is complicated and not well understood. Seemingly straightforward 93 fundamental information such as which genes are expressed therein and what functions they 94 perform are only partially characterized. To overcome these obstacles, we established the 95 CommonMind Consortium (CMC; www.synpase.org/CMC), a public-private partnership to 96 generate functional genomic data in brain samples obtained from autopsies of cases with and 97 without severe psychiatric disorders. The CMC is the largest existing collection of collaborating 98 brain banks and includes over 1,150 samples. A wide spectrum of data is being generated on 99 these samples including regional gene expression, epigenomics (cell-type specific histone 100 modifications and open chromatin), whole genome sequencing, and somatic mosaicism. 101 102 Schizophrenia (SCZ), affecting roughly 0.7% of adults, is a severe psychiatric disorder 103 characterized by abnormalities in thought and cognition (1). Despite a century of evidence 104 establishing its genetic basis, only recently have specific genetic risk factors been conclusively 105identified, including rare copy number variants (2) and >100 common variants (3). However, 106 there is not a one-to-one Mendelian mapping between these SCZ ris...

Recent molecular genetics studies implicate neuregulin 1 (NRG1) and its receptor erbB in the pathophysiology of schizophrenia. Among NRG1 receptors, erbB4 is of particular interest because of its crucial roles in neurodevelopment and in the modulation of N-methyl-D-aspartate (NMDA) receptor signaling. Here, using a new postmortem tissue-stimulation approach, we show a marked increase in NRG1-induced activation of erbB4 in the prefrontal cortex in schizophrenia. Levels of NRG1 and erbB4, however, did not differ between schizophrenia and control groups. To evaluate possible causes for this hyperactivation of erbB4 signaling, we examined the association of erbB4 with PSD-95 (postsynaptic density protein of 95 kDa), as this association has been shown to facilitate activation of erbB4. Schizophrenia subjects showed substantial increases in erbB4-PSD-95 interactions. We found that NRG1 stimulation suppresses NMDA receptor activation in the human prefrontal cortex, as previously reported in the rodent cortex. NRG1-induced suppression of NMDA receptor activation was more pronounced in schizophrenia subjects than in controls, consistent with enhanced NRG1-erbB4 signaling seen in this illness. Therefore, these findings suggest that enhanced NRG1 signaling may contribute to NMDA hypofunction in schizophrenia.